Aligos Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $27.78M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $27.78M 10-Q · filed 2026-08-06 |